131 related articles for article (PubMed ID: 32371242)
1. Effect of clinically significant thresholds of eosinophil elevation on health care resource use in asthma.
Dotiwala Z; Casciano J; Davis JR; Fox K; Gopalan G; Rastogi S; Lamerato L; Mathur SK
Ann Allergy Asthma Immunol; 2020 Aug; 125(2):182-189. PubMed ID: 32371242
[TBL] [Abstract][Full Text] [Related]
2. Burden of asthma with elevated blood eosinophil levels.
Casciano J; Krishnan JA; Small MB; Buck PO; Gopalan G; Li C; Kemp R; Dotiwala Z
BMC Pulm Med; 2016 Jul; 16(1):100. PubMed ID: 27412347
[TBL] [Abstract][Full Text] [Related]
3. High blood eosinophil count is a risk factor for future asthma exacerbations in adult persistent asthma.
Zeiger RS; Schatz M; Li Q; Chen W; Khatry DB; Gossage D; Tran TN
J Allergy Clin Immunol Pract; 2014; 2(6):741-50. PubMed ID: 25439366
[TBL] [Abstract][Full Text] [Related]
4. Clinical and Economic Burden of Elevated Blood Eosinophils in Patients With and Without Uncontrolled Asthma.
Casciano J; Krishnan J; Dotiwala Z; Li C; Sun SX
J Manag Care Spec Pharm; 2017 Jan; 23(1):85-91. PubMed ID: 28025926
[TBL] [Abstract][Full Text] [Related]
5. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
Ortega HG; Yancey SW; Mayer B; Gunsoy NB; Keene ON; Bleecker ER; Brightling CE; Pavord ID
Lancet Respir Med; 2016 Jul; 4(7):549-556. PubMed ID: 27177493
[TBL] [Abstract][Full Text] [Related]
6. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study.
Price DB; Rigazio A; Campbell JD; Bleecker ER; Corrigan CJ; Thomas M; Wenzel SE; Wilson AM; Small MB; Gopalan G; Ashton VL; Burden A; Hillyer EV; Kerkhof M; Pavord ID
Lancet Respir Med; 2015 Nov; 3(11):849-58. PubMed ID: 26493938
[TBL] [Abstract][Full Text] [Related]
7. Value of peripheral blood eosinophil markers to predict severity of asthma.
Casciano J; Krishnan JA; Small MB; Buck PO; Gopalan G; Li C; Kemp R; Dotiwala Z
BMC Pulm Med; 2016 Jul; 16(1):109. PubMed ID: 27473851
[TBL] [Abstract][Full Text] [Related]
8. Exacerbations and health care resource use among patients with COPD in relation to blood eosinophil counts.
Müllerová H; Hahn B; Simard EP; Mu G; Hatipoğlu U
Int J Chron Obstruct Pulmon Dis; 2019; 14():683-692. PubMed ID: 30962682
[TBL] [Abstract][Full Text] [Related]
9. Real-life retrospective observational study to determine the prevalence and economic burden of severe asthma in Spain.
Sicras-Mainar A; Capel M; Navarro-Artieda R; Nuevo J; Orellana M; Resler G
J Med Econ; 2020 May; 23(5):492-500. PubMed ID: 31958257
[No Abstract] [Full Text] [Related]
10. Burden of Chronic Oral Corticosteroid Use by Adults with Persistent Asthma.
Zeiger RS; Schatz M; Li Q; Chen W; Khatry DB; Tran TN
J Allergy Clin Immunol Pract; 2017; 5(4):1050-1060.e9. PubMed ID: 28215604
[TBL] [Abstract][Full Text] [Related]
11. The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies.
Goldman M; Hirsch I; Zangrilli JG; Newbold P; Xu X
Curr Med Res Opin; 2017 Sep; 33(9):1605-1613. PubMed ID: 28644104
[TBL] [Abstract][Full Text] [Related]
12. The burden of adult asthma in Finland: impact of disease severity and eosinophil count on health care resource utilization.
Viinanen A; Lassenius MI; Toppila I; Karlsson A; Veijalainen L; Idänpään-Heikkilä JJ; Laitinen T
J Asthma; 2020 Oct; 57(10):1092-1102. PubMed ID: 31267775
[No Abstract] [Full Text] [Related]
13. Evaluation of exacerbations and blood eosinophils in UK and US COPD populations.
Vogelmeier CF; Kostikas K; Fang J; Tian H; Jones B; Morgan CL; Fogel R; Gutzwiller FS; Cao H
Respir Res; 2019 Aug; 20(1):178. PubMed ID: 31391053
[TBL] [Abstract][Full Text] [Related]
14. Blood Eosinophil Count and Outcomes in Severe Uncontrolled Asthma: A Prospective Study.
Zeiger RS; Schatz M; Dalal AA; Chen W; Sadikova E; Suruki RY; Kawatkar AA; Qian L
J Allergy Clin Immunol Pract; 2017; 5(1):144-153.e8. PubMed ID: 27665383
[TBL] [Abstract][Full Text] [Related]
15. Disease burden and efficacy of mepolizumab in patients with severe asthma and blood eosinophil counts of ≥150-300 cells/μL.
Yancey SW; Bradford ES; Keene ON
Respir Med; 2019 May; 151():139-141. PubMed ID: 31047111
[TBL] [Abstract][Full Text] [Related]
16. Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease.
Yun JH; Lamb A; Chase R; Singh D; Parker MM; Saferali A; Vestbo J; Tal-Singer R; Castaldi PJ; Silverman EK; Hersh CP;
J Allergy Clin Immunol; 2018 Jun; 141(6):2037-2047.e10. PubMed ID: 29709670
[TBL] [Abstract][Full Text] [Related]
17. Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison.
Busse W; Chupp G; Nagase H; Albers FC; Doyle S; Shen Q; Bratton DJ; Gunsoy NB
J Allergy Clin Immunol; 2019 Jan; 143(1):190-200.e20. PubMed ID: 30205189
[TBL] [Abstract][Full Text] [Related]
18. Association of Blood Eosinophil and Blood Neutrophil Counts with Asthma Exacerbations in the Copenhagen General Population Study.
Vedel-Krogh S; Fallgaard Nielsen S; Lange P; Vestbo J; Nordestgaard BG
Clin Chem; 2017 Apr; 63(4):823-832. PubMed ID: 28209625
[TBL] [Abstract][Full Text] [Related]
19. Relationship of Blood Eosinophil Count to Exacerbations in Chronic Obstructive Pulmonary Disease.
Zeiger RS; Tran TN; Butler RK; Schatz M; Li Q; Khatry DB; Martin U; Kawatkar AA; Chen W
J Allergy Clin Immunol Pract; 2018; 6(3):944-954.e5. PubMed ID: 29153881
[TBL] [Abstract][Full Text] [Related]
20. Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma.
Albers FC; Licskai C; Chanez P; Bratton DJ; Bradford ES; Yancey SW; Kwon N; Quirce S
Respir Med; 2019 Nov; 159():105806. PubMed ID: 31751853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
